{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:05:21Z","timestamp":1786993521515,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Universit\u00e9 Libre de Bruxelles"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Visceral Surgery"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jviscsurg.2019.12.002","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T12:56:09Z","timestamp":1576500969000},"page":"79-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer"],"prefix":"10.1016","volume":"157","author":[{"given":"G.","family":"Liberale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-F.","family":"Pop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Polastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chintinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Larsimont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Nogaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Veys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0185","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 gynecologic cancer intergroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl 6","key":"10.1016\/j.jviscsurg.2019.12.002_bib0190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(10)70292-8","article-title":"New terminology for cytoreduction in advanced ovarian cancer","volume":"12","author":"Zapardiel","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0200","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1998.4955","article-title":"Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study","volume":"69","author":"Eisenkop","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0210","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2007.02.026","article-title":"Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival: an exploratory analysis of a prospectively randomized phase III study of the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group (AGOOVAR)","volume":"106","author":"Wimberger","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0220","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0225","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0230","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/IGC.0b013e31826a3559","article-title":"Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a retrospective French multicentric study","volume":"22","author":"Luyckx","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0235","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1245\/s10434-015-5051-9","article-title":"What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian cancer?","volume":"23","author":"Chiva","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0240","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0245","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0250","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1245\/s10434-012-2446-8","article-title":"Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer","volume":"19","author":"Chang","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0255","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ygyno.2013.05.006","article-title":"Optimal (\u22641cm) but visible residual disease: is extensive debulking warranted?","volume":"130","author":"Barlin","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0260","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s12885-015-1525-1","article-title":"Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study","volume":"15","author":"Ren","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0265","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ygyno.2006.06.028","article-title":"The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC\u2013IV epithelial ovarian cancer","volume":"103","author":"Eisenhauer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0270","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","article-title":"Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer","volume":"121","author":"Harter","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0275","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejso.2008.01.005","article-title":"Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients","volume":"35","author":"Colombo","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0280","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/AOG.0b013e31826981de","article-title":"Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer","volume":"120","author":"Wright","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0285","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/gyno.2000.5926","article-title":"A critique of surgical cytoreduction in advanced ovarian cancer","volume":"78","author":"Covens","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0290","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1200\/JCO.2005.02.1287","article-title":"Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial","volume":"23","author":"Crawford","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0295","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0300","first-page":"49","article-title":"Current methodologies for clinical assessment of patients with peritoneal carcinomatosis","volume":"15","author":"Jacquet","year":"1996","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0305","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIc or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0310","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.anchir.2004.07.002","article-title":"Surgical treatment of peritoneal carcinomatosis","volume":"129","author":"Elias","year":"2004","journal-title":"Ann Chir"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0315","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0320","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0325","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2006.11.002","article-title":"Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction","volume":"104","author":"Bristow","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0330","first-page":"209","article-title":"Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival","volume":"27","author":"Oksefjell","year":"2006","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0335","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2007.05.023","article-title":"Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up","volume":"106","author":"Scholz","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0340","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0345","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase iii trial of the gynecologic cancer intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2019.12.002_bib0350","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1245\/s10434-015-4387-5","article-title":"Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study","volume":"22","author":"Go\u00e9r\u00e9","year":"2015","journal-title":"Ann Surg Oncol"}],"container-title":["Journal of Visceral Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878788619301948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878788619301948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:32:13Z","timestamp":1761809533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878788619301948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1878788619301948"],"URL":"https:\/\/doi.org\/10.1016\/j.jviscsurg.2019.12.002","relation":{},"ISSN":["1878-7886"],"issn-type":[{"value":"1878-7886","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Visceral Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviscsurg.2019.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jchirv.2019.09.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}